Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Consolidated Edison, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $286.08 (market cap $39.89B), while Consolidated Edison, Inc. trades at $111.21 (market cap $40.95B). The key difference: Alnylam Pharmaceuticals, Inc. and Consolidated Edison, Inc. are close in size by market cap, and Consolidated Edison, Inc. pays a 3.13% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ED | |
|---|---|---|
Market Cap | $39.89B | $40.95B |
Sector | Health | Utilities |
52-Week High | $491.22 | $115.46 |
52-Week Low | $278.09 | $95.37 |
Enterprise Value | $38.15B | $67.98B |
Dividend Yield | — | 3.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Consolidated Edison (ED) trades at $111.12, up 0.76% on the day, with a bullish technical signal from moving averages and support near $110. The company reported revenue of $16.92B in 2025 with a net income margin of 12.52%, though Q1 2026 EPS missed expectations. Recent news highlights grid upgrades for AI data center demand and a new board member appointment, reinforcing its steady utility profile.
ED offers a defensive investment with a 3.3% dividend yield and 52-year growth streak, but faces risks from capital-intensive grid expansions and interest rate sensitivity. Analyst consensus is cautious with a $103.50 price target below current levels, suggesting limited near-term upside amid high hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
